Matthew L Sherman
CIK 1325710 · EVP & Chief Medical Officer · last filed 2024-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
XLRN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
200 SMITH STREET
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | EVP & Chief Medical Officer | 0 | $25.59 | $0 | -$445.2K | 21 | 2024-06-11 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Director | — | $13.60 | — | $0 | 7 | 2023-06-23 |
| LUMOS PHARMA, INC. (NLNK) Delisted | Director | — | — | — | $0 | 3 | 2019-08-02 |
| PULM | Director | 100 | $1.44 | $144 | $0 | 5 | 2019-05-20 |
| ACCELERON PHARMA INC (XLRN) Delisted | EVP & Chief Medical Officer | 77,267 | $178.75 | $13.81M | -$7.39M | 41 | 2018-04-04 |
Recent Filings · Page 2 of 8
77 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-10-05 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Sell (S) | −2,587 | -$48.5K | EDGAR |
| 2022-06-24 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-21 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Sell (S) | −1,768 | -$19.0K | EDGAR |
| 2022-02-18 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Sell (S) | −984 | -$8.9K | EDGAR |
| 2022-01-20 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | +20,500 | $0 | EDGAR |
| 2021-12-17 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | +11,100 | $0 | EDGAR |
| 2021-10-06 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Sell (S) | −2,659 | -$88.2K | EDGAR |
| 2021-06-29 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-18 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Mixed | +10,968 | -$6.5K | EDGAR |
| 2020-12-11 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Exer (M) | +207 | $7.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.